Cargando…

Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen

In general, a whole virion serves as a simple vaccine antigen and often essential material for the analysis of immune responses against virus infection. However, to work with highly contagious pathogens, it is necessary to take precautions against laboratory-acquired infection. We have learned many...

Descripción completa

Detalles Bibliográficos
Autor principal: Tsunetsugu-Yokota, Yasuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122600/
https://www.ncbi.nlm.nih.gov/pubmed/19057880
http://dx.doi.org/10.1007/978-1-59745-181-9_11
_version_ 1783515453689167872
author Tsunetsugu-Yokota, Yasuko
author_facet Tsunetsugu-Yokota, Yasuko
author_sort Tsunetsugu-Yokota, Yasuko
collection PubMed
description In general, a whole virion serves as a simple vaccine antigen and often essential material for the analysis of immune responses against virus infection. However, to work with highly contagious pathogens, it is necessary to take precautions against laboratory-acquired infection. We have learned many lessons from the recent outbreak of severe acute respiratory syndrome (SARS). In order to develop an effective vaccine and diagnostic tools, we prepared UV-inactivated SARS coronavirus on a large scale under the strict Biosafety Level 3 (BSL3) regulation. Our protocol for large-scale preparation of UV-inactivated SARS-CoV including virus expansion, titration, inactivation, and ultracentrifugation is applicable to any newly emerging virus we might encounter in the future.
format Online
Article
Text
id pubmed-7122600
institution National Center for Biotechnology Information
language English
publishDate 2007
record_format MEDLINE/PubMed
spelling pubmed-71226002020-04-06 Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen Tsunetsugu-Yokota, Yasuko SARS- and Other Coronaviruses Article In general, a whole virion serves as a simple vaccine antigen and often essential material for the analysis of immune responses against virus infection. However, to work with highly contagious pathogens, it is necessary to take precautions against laboratory-acquired infection. We have learned many lessons from the recent outbreak of severe acute respiratory syndrome (SARS). In order to develop an effective vaccine and diagnostic tools, we prepared UV-inactivated SARS coronavirus on a large scale under the strict Biosafety Level 3 (BSL3) regulation. Our protocol for large-scale preparation of UV-inactivated SARS-CoV including virus expansion, titration, inactivation, and ultracentrifugation is applicable to any newly emerging virus we might encounter in the future. 2007-11-28 /pmc/articles/PMC7122600/ /pubmed/19057880 http://dx.doi.org/10.1007/978-1-59745-181-9_11 Text en © Humana Press, a part of Springer Science+Business Media, LLC 2008 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Tsunetsugu-Yokota, Yasuko
Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
title Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
title_full Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
title_fullStr Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
title_full_unstemmed Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
title_short Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
title_sort large-scale preparation of uv-inactivated sars coronavirus virions for vaccine antigen
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122600/
https://www.ncbi.nlm.nih.gov/pubmed/19057880
http://dx.doi.org/10.1007/978-1-59745-181-9_11
work_keys_str_mv AT tsunetsuguyokotayasuko largescalepreparationofuvinactivatedsarscoronavirusvirionsforvaccineantigen